Singapore markets open in 1 hour 35 minutes
  • Straits Times Index

    3,388.52
    +7.68 (+0.23%)
     
  • S&P 500

    4,117.86
    -46.14 (-1.11%)
     
  • Dow

    33,949.01
    -207.68 (-0.61%)
     
  • Nasdaq

    11,910.52
    -203.27 (-1.68%)
     
  • BTC-USD

    22,896.25
    -363.37 (-1.56%)
     
  • CMC Crypto 200

    529.21
    -7.68 (-1.43%)
     
  • FTSE 100

    7,885.17
    +20.46 (+0.26%)
     
  • Gold

    1,887.80
    -2.90 (-0.15%)
     
  • Crude Oil

    78.43
    -0.04 (-0.05%)
     
  • 10-Yr Bond

    3.6530
    -0.0210 (-0.57%)
     
  • Nikkei

    27,606.46
    -79.01 (-0.29%)
     
  • Hang Seng

    21,283.52
    -15.18 (-0.07%)
     
  • FTSE Bursa Malaysia

    1,470.75
    -5.63 (-0.38%)
     
  • Jakarta Composite Index

    6,940.12
    +4.82 (+0.07%)
     
  • PSE Index

    6,923.08
    +41.82 (+0.61%)
     

Lonza's first-half core EBITDA gains 16.5%

FILE PHOTO: Logo of Swiss pharmaceutical group Lonza is seen in Basel

By Ludwig Burger

(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies.

First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs.

For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.

The company is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins as well as cell and gene therapies. Under the plan, Lonza earlier this month announced a 500 million franc investment in Switzerland to fill biotech drugs into vials.

The company, which is a key supplier of vaccine maker Moderna, is banking on long-term growth in the biopharmaceuticals sector well beyond the pandemic.

(Reporting by Ludwig Burger, Editing by Miranda Murray)